Pridopidine Reverses Phencyclidine-Induced Memory Impairment
Pridopidine is in clinical trials for Huntington's disease treatment. Originally developed as a dopamine D receptor (D R) ligand, pridopidine displays about 100-fold higher affinity for the sigma-1 receptor (sigma-1R). Interestingly, pridopidine slows disease progression and improves motor func...
Saved in:
Published in | Frontiers in pharmacology Vol. 9; p. 338 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media
10.04.2018
Frontiers Media S.A |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pridopidine is in clinical trials for Huntington's disease treatment. Originally developed as a dopamine D
receptor (D
R) ligand, pridopidine displays about 100-fold higher affinity for the sigma-1 receptor (sigma-1R). Interestingly, pridopidine slows disease progression and improves motor function in Huntington's disease model mice and, in preliminarily reports, Huntington's disease patients. The present study examined the anti-amnesic potential of pridopidine. Thus, memory impairment was produced in mice by administration of phencyclidine (PCP, 10 mg/kg/day) for 10 days, followed by 14 days' treatment with pridopidine (6 mg/kg/day), or saline. Finally, novel object recognition performance was assessed in the animals. Mice receiving PCP and saline exhibited deficits in novel object recognition, as expected, while pridopidine treatment counteracted PCP-induced memory impairment. The effect of pridopidine was attenuated by co-administration of the sigma receptor antagonist, NE-100 (10 mg/kg). Our results suggest that pridopidine exerts anti-amnesic and potentially neuroprotective actions. These data provide new insights into the therapeutic potential of pridopidine as a pro-cognitive drug. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Luis F. Callado, University of the Basque Country (UPV/EHU), Spain Reviewed by: Dasiel Oscar Borroto-Escuela, Karolinska Institute (KI), Sweden; Karolina Pytka, Jagiellonian University, Poland This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology These authors have contributed equally to this work. |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2018.00338 |